Iranian Journal of Medical Sciences

Document Type : Original Article(s)

Authors

1 Department of Immunology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

2 Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

3 Health Metrics and Evaluation Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

4 Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

5 Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

10.30476/ijms.2026.109059.4425

Abstract

Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD). Neutrophil extracellular traps (NETs) have been recognized as contributing to UC progression. This study aimed to identify key genes driving NET formation in UC and evaluate their potential as biomarkers.
Methods: Gene expression profiles from colon biopsies of UC patients and healthy controls were obtained from the GSE224758 dataset. Differentially expressed genes (DEGs) were identified using the GEO2R tool. Hub genes involved in NET formation, including FCGR3B, AQP9, FPR1, FPR2, and NCF2, were validated through reverse transcription-quantitative polymerase chain reaction (RT-qPCR) using colon biopsy samples from healthy controls (n=20), newly diagnosed UC (n=20), and treatment-resistant UC patients (n=20) collected between November 8, 2022, and February 2, 2025, at Tohid Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran. Data normality was assessed using the Shapiro–Wilk test; Kruskal–Wallis test and Dunn’s 
post hoc test were applied for group comparisons. ROC analysis was applied to determine the potential of genes for the differentiation of healthy people from patients.
Results: RT-qPCR validation confirmed significantly increased expression of AQP9 (P <0.0001), FPR1, and FPR2 (P=0.03 and P=0.02) genes in patients with UC and those with refractory UC compared to healthy controls. Among these, AQP9 exhibited the most significant differential expression, demonstrating high sensitivity and specificity in distinguishing newly diagnosed and treatment-resistant UC patients from healthy individuals (sensitivity 83.49% and 80.98%, and specificity 67.77% and 64.24%, respectively), indicating its potential as a diagnostic biomarker. 
Conclusion: This study identifies NET-associated genes, particularly AQP9, FPR1, and FPR2, as candidate tissue biomarkers for UC, with AQP9 exhibiting the strongest ability to distinguish patients from healthy controls. These findings support the utility of NET-related genes as tissue biomarkers for UC, while emphasizing that any therapeutic targeting of these molecules lies beyond the scope of the present work and will require additional functional and in vivo validation.

Highlights

Hawra Zia Hossein al-Jamali (Google Scholar)   
Shohreh Fakhari (Google Scholar)   

Keywords

  1. Sosna B, Aebisher D, Myśliwiec A, Dynarowicz K, Bartusik-Aebisher D, Oleś P, et al. Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease. Int J Mol Sci. 2023;25. doi: 10.3390/ijms25010202. PubMed PMID: 38203373; PubMed Central PMCID: PMC10779120.
  2. Tanwar P, Naagar M, Maity MK. A review on Ulcerative Colitis: Epidemiology, Risk Factors, Pathophysiology, Diagnosis, Clinical Management and Treatment Modalities. International Journal of Enhanced Research in Medicines & Dental Care. 2023;10:15-29.
  3. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician. 2007;76:1323-30. PubMed PMID: 18019875.
  4. Burri E, Maillard MH, Schoepfer AM, Seibold F, Van Assche G, Rivière P, et al. Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update. Digestion. 2020;101:2-15. doi: 10.1159/000504092. PubMed PMID: 31945767.
  5. van Lierop PP, Samsom JN, Escher JC, Nieuwenhuis EE. Role of the innate immune system in the pathogenesis of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:142-51. doi: 10.1097/MPG.0b013e3181821964. PubMed PMID: 19179875.
  6. Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, et al. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018;24:5-14. doi: 10.3748/wjg.v24.i1.5. PubMed PMID: 29358877; PubMed Central PMCID: PMC5757125.
  7. Zhou G, Yu L, Fang L, Yang W, Yu T, Miao Y, et al. CD177(+) neutrophils as functionally activated neutrophils negatively regulate IBD. Gut. 2018;67:1052-63. doi: 10.1136/gutjnl-2016-313535. PubMed PMID: 28468761.
  8. Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, et al. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. Int J Mol Med. 2018;41:107-18. doi: 10.3892/ijmm.2017.3244. PubMed PMID: 29115397; PubMed Central PMCID: PMC5746327.
  9. Drury B, Hardisty G, Gray RD, Ho GT. Neutrophil Extracellular Traps in Inflammatory Bowel Disease: Pathogenic Mechanisms and Clinical Translation. Cell Mol Gastroenterol Hepatol. 2021;12:321-33. doi: 10.1016/j.jcmgh.2021.03.002. PubMed PMID: 33689803; PubMed Central PMCID: PMC8166923.
  10. Long D, Mao C, Xu Y, Zhu Y. The emerging role of neutrophil extracellular traps in ulcerative colitis. Front Immunol. 2024;15:1425251. doi: 10.3389/fimmu.2024.1425251. PubMed PMID: 39170617; PubMed Central PMCID: PMC11335521.
  11. Josefs T, Barrett TJ, Brown EJ, Quezada A, Wu X, Voisin M, et al. Neutrophil extracellular traps promote macrophage inflammation and impair atherosclerosis resolution in diabetic mice. JCI Insight. 2020;5. doi: 10.1172/jci.insight.134796. PubMed PMID: 32191637; PubMed Central PMCID: PMC7205252.
  12. Kim TS, Silva LM, Theofilou VI, Greenwell-Wild T, Li L, Williams DW, et al. Neutrophil extracellular traps and extracellular histones potentiate IL-17 inflammation in periodontitis. J Exp Med. 2023;220. doi: 10.1084/jem.20221751. PubMed PMID: 37261457; PubMed Central PMCID: PMC10236943.
  13. Zhang Y, Guo L, Dai Q, Shang B, Xiao T, Di X, et al. A signature for pan-cancer prognosis based on neutrophil extracellular traps. J Immunother Cancer. 2022;10. doi: 10.1136/jitc-2021-004210. PubMed PMID: 35688556; PubMed Central PMCID: PMC9189842.
  14. Li J, Liu Y, Sun Z, Zeng S, Zheng C. Identification of neutrophil extracellular trap-related biomarkers in ulcerative colitis based on bioinformatics and machine learning. Front Genet. 2025;16:1589999. doi: 10.3389/fgene.2025.1589999. PubMed PMID: 40620701; PubMed Central PMCID: PMC12226468.
  15. Xv Y, Feng Y, Lin J. CXCR1 and CXCR2 are potential neutrophil extracellular trap-related treatment targets in ulcerative colitis: insights from Mendelian randomization, colocalization and transcriptomic analysis. Front Immunol. 2024;15:1425363. doi: 10.3389/fimmu.2024.1425363. PubMed PMID: 39328405; PubMed Central PMCID: PMC11424450.
  16. Ou J, Li L, Zhi F, Huang B, Zhao X. Developing models for the diagnosing of ulcerative colitis and prognosis of anti-TNF-α non-response based on neutrophil extracellular trap-associated genes. Front Immunol. 2025;16:1530508. doi: 10.3389/fimmu.2025.1530508. PubMed PMID: 40963602; PubMed Central PMCID: PMC12436428.
  17. Alemán OR, Mora N, Cortes-Vieyra R, Uribe-Querol E, Rosales C. Differential Use of Human Neutrophil Fcγ Receptors for Inducing Neutrophil Extracellular Trap Formation. J Immunol Res. 2016;2016:2908034. doi: 10.1155/2016/2908034. PubMed PMID: 27034964; PubMed Central PMCID: PMC4806689.
  18. Liang P, Zhu M, Sun X, Wang L, Li B, Ming S, et al. LncRNA-mRNA co-expression analysis reveals aquaporin-9-promoted neutrophil extracellular trap formation and inflammatory activation in sepsis. Int Immunopharmacol. 2024;140:112916. doi: 10.1016/j.intimp.2024.112916. PubMed PMID: 39133961.
  19. da Silva IV, Garra S, Calamita G, Soveral G. The Multifaceted Role of Aquaporin-9 in Health and Its Potential as a Clinical Biomarker. Biomolecules. 2022;12. doi: 10.3390/biom12070897. PubMed PMID: 35883453; PubMed Central PMCID: PMC9313442.
  20. Nafiz TN, Sankar P, Mishra LK, Rousseau RP, Saqib M, Subbian S, et al. Differential requirement of formyl peptide receptor 1 in macrophages and neutrophils in the host defense against Mycobacterium tuberculosis Infection. Sci Rep. 2024;14:23595. doi: 10.1038/s41598-024-71180-1. PubMed PMID: 39384825; PubMed Central PMCID: PMC11464745.
  21. Lou X, Chen H, Chen S, Ji H, He T, Chen H, et al. LL37/FPR2 regulates neutrophil mPTP promoting the development of neutrophil extracellular traps in diabetic retinopathy. Faseb j. 2024;38:e23697. doi: 10.1096/fj.202400656R. PubMed PMID: 38842874.
  22. Yi X, Tran E, Odiba JO, Qin CX, Ritchie RH, Baell JB. The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists. Eur J Med Chem. 2024;265:115989. doi: 10.1016/j.ejmech.2023.115989. PubMed PMID: 38199163.
  23. Song Z, Yoo DG, Idol RA, Barbu EA, Jacob CO, Dinauer MC. Lupus-associated NCF2 variant p.R395W in the NADPH oxidase 2 complex results in a reduced production of reactive oxygen species by myeloid cells. Front Lupus. 2023;1:1186641. doi: 10.3389/flupu.2023.1186641.
  24. Garley M, Dziemiańczyk-Pakieła D, Ratajczak-Wrona W, Pryczynicz A, Nowak K, Łazarczyk B, et al. NETs biomarkers in saliva and serum OSCC patients: One hypothesis, two conclusions. Adv Med Sci. 2022;67:45-54. doi: 10.1016/j.advms.2021.12.004. PubMed PMID: 34971930.
  25. Muise AM, Xu W, Guo CH, Walters TD, Wolters VM, Fattouh R, et al. NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut. 2012;61:1028-35. doi: 10.1136/gutjnl-2011-300078. PubMed PMID: 21900546; PubMed Central PMCID: PMC3806486.
  26. Fakhari S, Moradzad M, Ahmadi A, Hekmatnia M, Jalili A, Nikkhoo B, et al. Downregulation of MT2-MMP and MT5-MMP in ulcerative colitis serves a diagnostic predictor and potential therapeutic targets. Mol Biol Rep. 2025;52:359. doi: 10.1007/s11033-025-10449-8. PubMed PMID: 40178713.
  27. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101-8. doi: 10.1038/nprot.2008.73. PubMed PMID: 18546601.
  28. Rump K, Adamzik M. Aquaporins in sepsis- an update. Front Immunol. 2024;15:1495206. doi: 10.3389/fimmu.2024.1495206. PubMed PMID: 39544938; PubMed Central PMCID: PMC11560437.
  29. Liu X, Xu Q, Li Z, Xiong B. Integrated analysis identifies AQP9 correlates with immune infiltration and acts as a prognosticator in multiple cancers. Sci Rep. 2020;10:20795. doi: 10.1038/s41598-020-77657-z. PubMed PMID: 33247170; PubMed Central PMCID: PMC7699650.
  30. Escudero-Hernández C, Münch A, Østvik AE, Granlund AVB, Koch S. The Water Channel Aquaporin 8 is a Critical Regulator of Intestinal Fluid Homeostasis in Collagenous Colitis. J Crohns Colitis. 2020;14:962-73. doi: 10.1093/ecco-jcc/jjaa020. PubMed PMID: 32016376; PubMed Central PMCID: PMC7393183.
  31. Ricanek P, Lunde LK, Frye SA, Støen M, Nygård S, Morth JP, et al. Reduced expression of aquaporins in human intestinal mucosa in early stage inflammatory bowel disease. Clin Exp Gastroenterol. 2015;8:49-67. doi: 10.2147/ceg.s70119. PubMed PMID: 25624769; PubMed Central PMCID: PMC4296881.
  32. Yu B, Yin YX, Tang YP, Wei KL, Pan ZG, Li KZ, et al. Diagnostic and Predictive Value of Immune-Related Genes in Crohn’s Disease. Front Immunol. 2021;12:643036. doi: 10.3389/fimmu.2021.643036. PubMed PMID: 33936061; PubMed Central PMCID: PMC8085323.
  33. Yu M, Shi Y, Gao Y, Luo Y, Jin Y, Liang X, et al. Targeting AQP9 enhanced the anti-TNF therapy response in Crohn’s disease by inhibiting LPA-hippo pathway. Pharmacol Res. 2024;203:107172. doi: 10.1016/j.phrs.2024.107172. PubMed PMID: 38583685.
  34. McAllister MJ, Hall R, Whelan RJ, Fischer LJ, Chuah CS, Cartlidge PD, et al. Formylated Peptide Receptor-1-Mediated Gut Inflammation as a Therapeutic Target in Inflammatory Bowel Disease. Crohns Colitis 360. 2024;6:otae003. doi: 10.1093/crocol/otae003. PubMed PMID: 38352118; PubMed Central PMCID: PMC10862654.
  35. Ye C, Zhu S, Yuan J, Yuan X. FPR1, as a Potential Biomarker of Diagnosis and Infliximab Therapy Responses for Crohn’s Disease, is Related to Disease Activity, Inflammation and Macrophage Polarization. J Inflamm Res. 2024;17:3949-66. doi: 10.2147/jir.s459819. PubMed PMID: 38911989; PubMed Central PMCID: PMC11193993.
  36. Yang WS, Wang JL, Wu W, Wang GF, Yan J, Liu Q, et al. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease. Acta Pharmacol Sin. 2023;44:19-31. doi: 10.1038/s41401-022-00944-0. PubMed PMID: 35840658; PubMed Central PMCID: PMC9812994.
  37. Asano K, Matsumoto T, Umeno J, Hirano A, Esaki M, Hosono N, et al. Impact of allele copy number of polymorphisms in FCGR3A and FCGR3B genes on susceptibility to ulcerative colitis. Inflamm Bowel Dis. 2013;19:2061-8. doi: 10.1097/MIB.0b013e318298118e. PubMed PMID: 23917248.